Baseline characteristics of patients with suspected HIT
| Characteristics . | HIT negative . | HIT positive . | Missing data . | |
|---|---|---|---|---|
| H/PF4-ab negative . | H/PF4-ab positive . | HIPA positive . | ||
| n | 1201 | 73 | 119 | |
| Male sex, n (%) | 765 (63.9) | 51 (69.9) | 71 (59.7) | |
| Age, median (IQR) | 67.25 (58.05-75.19) | 61.31 (54.23-75.88) | 64.65 (55.50-74.48) | |
| Setting, n (%) | 1 (0.1) | |||
| ICU | 443 (36.9) | 36 (49.3) | 40 (33.6) | |
| Cardiovascular surgery | 376 (31.3) | 20 (27.4) | 47 (39.5) | |
| Internal medicine | 246 (20.5) | 11 (15.1) | 16 (13.4) | |
| General surgery | 118 (9.8) | 5 (6.8) | 9 (7.6) | |
| Major trauma | 4 (0.3) | 0 (0.0) | 6 (5.0) | |
| Other | 13 (1.1) | 1 (1.4) | 1 (0.8) | |
| Sepsis, n (%) | 578 (48.1) | 42 (57.5) | 57 (47.9) | 0 (0.0) |
| CRP, median (IQR), mg/L | 89 (35-176) | 64 (20-150) | 87 (44-146) | 86 (6.2) |
| SARS-CoV-2 infection, n (%) | 67 (5.6) | 15 (20.8) | 7 (5.9) | 9 (0.6) |
| Unfractionated heparin, n (%) | 934 (77.8) | 61 (83.6) | 103 (86.6) | 0 (0.0) |
| 4Ts score, median (IQR) | 3 (2-4) | 4 (3-5) | 5 (4-6) | 0 (0.0) |
| Platelet nadir, median (IQR), ×109/L | 60 (38-85) | 76 (46-115) | 52 (32-73) | 22 (1.6) |
| CLIA, median (IQR), U/mL | 0.0 (0.00-0.09) | 2.27 (1.48-4.90) | 10.35 (3.76-24.59) | 75 (5.4) |
| Characteristics . | HIT negative . | HIT positive . | Missing data . | |
|---|---|---|---|---|
| H/PF4-ab negative . | H/PF4-ab positive . | HIPA positive . | ||
| n | 1201 | 73 | 119 | |
| Male sex, n (%) | 765 (63.9) | 51 (69.9) | 71 (59.7) | |
| Age, median (IQR) | 67.25 (58.05-75.19) | 61.31 (54.23-75.88) | 64.65 (55.50-74.48) | |
| Setting, n (%) | 1 (0.1) | |||
| ICU | 443 (36.9) | 36 (49.3) | 40 (33.6) | |
| Cardiovascular surgery | 376 (31.3) | 20 (27.4) | 47 (39.5) | |
| Internal medicine | 246 (20.5) | 11 (15.1) | 16 (13.4) | |
| General surgery | 118 (9.8) | 5 (6.8) | 9 (7.6) | |
| Major trauma | 4 (0.3) | 0 (0.0) | 6 (5.0) | |
| Other | 13 (1.1) | 1 (1.4) | 1 (0.8) | |
| Sepsis, n (%) | 578 (48.1) | 42 (57.5) | 57 (47.9) | 0 (0.0) |
| CRP, median (IQR), mg/L | 89 (35-176) | 64 (20-150) | 87 (44-146) | 86 (6.2) |
| SARS-CoV-2 infection, n (%) | 67 (5.6) | 15 (20.8) | 7 (5.9) | 9 (0.6) |
| Unfractionated heparin, n (%) | 934 (77.8) | 61 (83.6) | 103 (86.6) | 0 (0.0) |
| 4Ts score, median (IQR) | 3 (2-4) | 4 (3-5) | 5 (4-6) | 0 (0.0) |
| Platelet nadir, median (IQR), ×109/L | 60 (38-85) | 76 (46-115) | 52 (32-73) | 22 (1.6) |
| CLIA, median (IQR), U/mL | 0.0 (0.00-0.09) | 2.27 (1.48-4.90) | 10.35 (3.76-24.59) | 75 (5.4) |
This table presents demographic, clinical, and laboratory characteristics of 1393 consecutive patients included in a prospective, multicenter cohort study. Patients were stratified into 3 groups: (1) HIT-negative without heparin/PF4 antibodies, (2) HIT-negative with heparin/PF4 antibodies, and (3) HIT-positive, defined by a positive washed-platelet HIPA test.
ab, antibody; CLIA, chemiluminescent immunoassay capturing antibodies against heparin/PF4 complexes; CRP, C-reactive protein; ICU, intensive care unit; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.